aRigen Inc., Japanese Bioventure Company, Announces Start Of US Clinical Study Of Novel Anti-Staph Antibiotic By Catalyst CRO
10/19/2005 5:11:32 PM
aRigen Inc. (aRigen) a privately held, bioventure company headquartered in Tokyo, Japan announced initiation of their Phase I, single dose study of WAP 8294A2 (WAP). WAP has a unique mechanism of action and potent antimicrobial efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and other drug resistant strains.
comments powered by